Zohydro ER is indicated for managing pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
You Might Also Like
Explore This IssueMarch 2015
Also By This Author
Michele B. Kaufman, PharmD, CGP, RPh, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.
- Bykerk VP, Cush J, Winthrop K, et al. Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials. Ann Rheum Dis. 2015;74(1):96–103.
- Alder Biopharmaceuticals. Pipeline. Feb. 2, 2015. http://www.alderbio.com/therapeutics/pipeline.
- Mease P, Gottlieb AB, Berman A, et al. A Phase IIb, randomized, double-blind, placebo-controlled, dose-ranging, multicenter study to evaluate the efficacy and safety of clazakizumab, an anti-il-6 monoclonal antibody, in adults with active psoriatic arthritis. Arthritis Rheumatol. 2014;66(11):Suppl. Abstract 952.
- Zogenix receives FDA approval of new formulation of Zohydro ER. First Word Pharma. 2015 Feb 1. http://www.firstwordpharma.com/print/1261369?tsid=17.